Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 2  |  Page : 251-257

Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea


1 Department of Urology, National Police Hospital, Seoul, Korea
2 Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea
3 Department of Pathology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea

Correspondence Address:
Kang Hyun Lee
Center for Prostate Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi, 410-769
Korea
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.136546

Rights and Permissions

Aim: We retrospectively reviewed the treatment outcomes of docetaxel plus prednisolone chemotherapy in Korean men with metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods: This Study included 106 consecutive Korean patients with mCRPC who were treated with a 3-weekly regimen of docetaxel plus prednisolone chemotherapy between 2005 and 2011. The oncologic results and treatment-related adverse events were analyzed. Results: The mean patient age was 66 years. Of the 106 patients, 70 (66.0%) received docetaxel as the first-line chemotherapy. A 50% reduction in prostate-specific antigen and objective response in measurable lesion were observed in 45 (48.9%) and 14 (17.9%) patients respectively. Fifteen (14.4%) patients experienced grade 3 or higher neutropenic fever. One patient had a treatment-related death. median follow-up time was 26.5 months. The median progression-free survival and overall survival (OS) were 6.0 and 16.0 months respectively. Of several factors examined, multivariate analysis Identified good performance status and first-line setting predict longer OS. The median OS of the patients in the first- and second-line setting was 23.0 versus 11.0 months (Hazard ratio 2.485, 95% confidence interval 1.558-3.966, P < 0.001). The survival rates in the first-line at 12 and 24 months were 73.8% and 47.2% respectively. Conclusion: Korean castration-resistant prostate cancer patients that receive docetaxel chemotherapy have a relatively longer survival outcome compared with western countries in the first-line setting. In addition, good performance status and first-line setting predicts longer survival. A prospective study including genetic background associated with the prognosis of mCRPC patients might be required.

Abstract in Chinese

多西他赛联合氢化泼尼松治疗转移性去势失败的前列腺癌在朝鲜族人中的研究 摘要 目的:回顾性分析多西紫杉醇联合氢化泼尼松化疗在韩国男性的去势治疗失败的转移性前列腺癌(mCRPC)的治疗效果。 方法:收集2005年-2011年106例mCRPC患者,均接受每3周多西紫杉醇联合联合氢化泼尼松化疗治疗。分析临床病理因素与治疗相关的不良事件。 结果:患者的平均年龄为66年。106例中,70例(66%)接受多西他赛作为一线化疗。45例(48.9%)患者前列腺特异性抗原降低50%,14例(17.9%)可测量病灶减少50%。15例(14.4%)患者出现三或更高的中性粒细胞减少伴发热。治疗相关的死亡一例病人。中位随访时间为26.5个月,平均无进展生存时间和总生存时间(OS)分别为6.0和16.0个月。多因素分析显示,良好的身体状态和好的一线治疗预示病人将有较长的总生存时间。一线和二线治疗的患者的中位OS为23.0与11.0个月(危险比2.485,95%可信区间1.558,3.966,P<0.001)。一线治疗在12和24个月的存活率分别为73.8%和47.2%。 结论:与西方国家相比,朝鲜族去势失效的前列腺癌患者接受多西紫杉醇化疗有一个相对较长的生存结果。此外,良好的身体状态和好的一线治疗的预示生存期较长。前瞻性研究包括遗传背景相关的mCRPC患者的预后可能是必要的。 关键词:多烯紫杉醇,前列腺癌,生存,毒性



[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2782    
    Printed93    
    Emailed3    
    PDF Downloaded160    
    Comments [Add]    

Recommend this journal